Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | EP300 | Q09472 | 2/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | PLG | P00747 | 1/20 | 0.45 |
| ▸ | ELANE | P08246 | 1/20 | 0.45 |
| ▸ | CTSG | P08311 | 1/20 | 0.45 |
| ▸ | CMA1 | P23946 | 1/20 | 0.45 |
| ▸ | CTRC | Q99895 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17961704 | 1.00 | ADORA2A (0.48) | ADORA2AEP300F2PLGELANE | |
| SCHEMBL9771410 | 0.92 | POLB (0.51) | ADORA2AEP300TP53POLBALDH1A1 | |
| SCHEMBL9771405 | 0.91 | TP53 (0.53) | ADORA2ATP53POLBALDH1A1KMT2A | |
| SCHEMBL9771367 | 0.88 | MEN1 (0.54) | EP300CMA1ALDH1A1KMT2AMEN1 | |
| SCHEMBL9771317 | 0.87 | POLB (0.55) | POLBALDH1A1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL9771398 | 0.83 | ADORA2A (0.48) | ADORA2AEP300F2PLGELANE | |
| SCHEMBL9771359 | 0.81 | POLB (0.39) | TP53POLBALDH1A1KMT2AMEN1 | |
| SCHEMBL10073003 | 0.81 | CMA1 (0.51) | CMA1TP53POLBALDH1A1KMT2A | |
| SCHEMBL14019658 | 0.80 | POLB (0.46) | TP53POLBALDH1A1SMN1; SMN2 | |
| SCHEMBL9771422 | 0.74 | EP300 (0.49) | ADORA2AEP300F2PLGELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9522922-B2 | Process for the preparation of intermediate for the preparation of oseltamivir phosphate | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2016-12-20 | — | — | US | disclosed |
| US-20160222029-A1 | A PROCESS FOR THE PREPARATION OF INTERMEDIATE FOR THE PREPARATION OF OSELTAMIVIR PHOSPHATE | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2016-08-04 | — | — | US | disclosed |
| US-5250699-A | Intermediates in the preparation of biotins | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1993-10-05 | — | — | US | disclosed |
| US-5095118-A | PROCESS FOR THE PREPARATION OF D-(+)-BIOTIN | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1992-03-10 | — | — | US | disclosed |
| EP-0242686-B1 | PROCESS FOR THE PREPARATION OF D-(+)-BIOTINE | MERCK PATENT GmbH (DE) | 1992-01-29 | — | — | EP | disclosed |
| US-5068341-A | OPTICALLY ACTIVE HYDANTOINS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1991-11-26 | — | — | US | disclosed |
| EP-0439564-A1 | PROCESS FOR PREPARING D-(+)-BIOTIN | MERCK PATENT GmbH (DE) | 1991-08-07 | — | — | EP | disclosed |
| EP-0243734-B1 | OPTICALLY ACTIVE HYDANTOIN | MERCK PATENT GmbH (DE) | 1991-07-17 | — | — | EP | disclosed |
| WO-1991002734-A1 | PROCESS FOR PREPARING D-(+)-BIOTIN | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1991-03-07 | — | — | WO | disclosed |
| US-4937351-A | Process for the preparation of D-(+)-biotin | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1990-06-26 | — | — | US | disclosed |
| US-4877882-A | Process for the preparation of D-(+)-biotin | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1989-10-31 | — | — | US | disclosed |
| US-4837402-A | Process for the preparation of D-(+)-biotin | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1989-06-06 | — | — | US | disclosed |
| US-4732987-A | Process for the preparation of D-(+)-biotin | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1988-03-22 | — | — | US | disclosed |
| EP-0243734-A2 | Optically active hydantoin | MERCK PATENT GmbH (DE) | 1987-11-04 | — | — | EP | disclosed |
| EP-0242686-A2 | Process for the preparation of D-(+)-biotine | MERCK PATENT GmbH (DE) | 1987-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160222029-A1 | A PROCESS FOR THE PREPARATION OF INTERMEDIATE FOR THE PREPARATION OF OSELTAMIVIR PHOSPHATE | OSGEP, CYP2B6, CYP2F1 | ADORA2A 260/4885EP300 4547/4885F2 3617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.